RIDLY/Health corpora/Dermatology
Dermatology / Feasibility review

Dermatology Symptoms & Treatment Response

Skin symptom reports, flares and treatment experience, with image and report coverage assessed separately.

Request corpus feasibility Review the scope
Available for feasibility inquiries. Data access, cohort coverage and permitted uses require verification before a license is offered.

Define the corpus

Request a dermatology cohort assessment combining patient-reported symptoms and treatment history. Image-based work can be scoped where suitable photographs or reports, source quality and image-use rights can be verified.

Fields to assess

  • Reported itch, pain, symptom severity and flares
  • Treatment use and reported response
  • Patient-reported daily impact
  • Eligible photographs, imaging reports and clinical documents

Field-level coverage, missingness and provenance are confirmed during feasibility review. Listed modalities are not a promise of availability.

Project applications

  • Longitudinal symptom burden
  • Treatment-pattern analysis
  • Patient-reported dermatology outcomes
  • Image-evaluation feasibility

Data interpretation

Clinical photographs, scanned reports and original DICOM studies are different modalities. No annotated image collection or DICOM availability is implied.

Cohort and delivery specification

Request the condition definition, unique participant count, geography, observation period, follow-up distribution, field coverage and update schedule. The specification distinguishes self-reported observations, device measurements and clinical-record-derived fields.

Clinical coding, measurement units, data dictionaries, missingness and de-identification are reviewed for the proposed delivery. Clinical images and reports are assessed separately from original DICOM studies; genetic test summaries are assessed separately from raw variants, sequencing and omics matrices.

Licensing and due diligence

Annual licenses, defined-project access and refreshes can be discussed after feasibility review. Research, AI evaluation, model training, derivative models, sublicensing and exclusivity require specific written permissions. Patient recontact is not included in an inquiry or implied by a data license.

Source provenance, the legal supplier or controller and its authority to license are disclosed during buyer due diligence. These profiles may draw on overlapping populations; counts are not added across products.

Tell us the cohort you need.

Include conditions, required fields, follow-up and intended use. No patient records are needed to make an inquiry.

Contact RIDLY